Valrubicin

In this article, we are going to explore Valrubicin and its impact on today's society. Valrubicin is a topic that has generated great interest in recent times, since its influence extends to different areas of daily life. Since its appearance, Valrubicin has sparked debate and reflection in various sectors, which has led to an in-depth analysis of its implications. In this sense, it is interesting to know more about Valrubicin and how it has evolved over time, as well as its relevance in the current context. Therefore, in the next few lines, we will delve into the multiple facets of Valrubicin and its role in contemporary society.

Valrubicin
Clinical data
AHFS/Drugs.comConsumer Drug Information
MedlinePlusa611021
Routes of
administration		Intravesical
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
BioavailabilityNegligible
Protein binding>99%
MetabolismNegligible
ExcretionIn urine
Identifiers
  • 2-oxo-2-hexopyranosyl}oxy)-1,2,3,4,6,11-hexahydrotetracen-2-yl]ethyl pentanoate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.205.793 Edit this at Wikidata
Chemical and physical data
FormulaC34H36F3NO13
Molar mass723.651 g·mol−1
3D model (JSmol)
  • FC(F)(F)C(=O)N5(O)(O(O4c3c(O)c2C(=O)c1c(OC)cccc1C(=O)c2c(O)c3C(O)(C(=O)COC(=O)CCCC)C4)C5)C
  • InChI=1S/C34H36F3NO13/c1-4-5-9-21(40)49-13-20(39)33(47)11-16-24(19(12-33)51-22-10-17(27(41)14(2)50-22)38-32(46)34(35,36)37)31(45)26-25(29(16)43)28(42)15-7-6-8-18(48-3)23(15)30(26)44/h6-8,14,17,19,22,27,41,43,45,47H,4-5,9-13H2,1-3H3,(H,38,46)/t14-,17-,19-,22-,27+,33-/m0/s1 checkY
  • Key:ZOCKGBMQLCSHFP-KQRAQHLDSA-N checkY
  (verify)

Valrubicin (N-trifluoroacetyladriamycin-14-valerate, trade name Valstar) is a chemotherapy drug used to treat bladder cancer. Valrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder.

It was originally launched as Valstar in the U.S. in 1999 for intravesical therapy of Bacille Calmette-Guérin (BCG)-refractory carcinoma in situ of the urinary bladder in patients in whom cystectomy would be associated with unacceptable morbidity or mortality; however, it was voluntarily withdrawn in 2002 due to manufacturing issues.[1] Valstar was relaunched on September 3, 2009.[2]

Side effects

References

  1. ^ "Manufacturing Issues Remain for Indevus' Valstar", U.S. Food and Drug Administration News. The MQN Weekly Bulletin, Jan. 11, 2008
  2. ^ "Endo Pharmaceuticals launches VALSTAR for treating recurrent carcinoma in situ bladder tumors" (Press release). 2009-09-03. Retrieved 2009-11-26.